VARIAGENICS Annouces Webcast of Panel Discussion At the Thomas Weisel Partners Healthcare Tailwinds Conference
CAMBRIDGE, Mass.--(BW HealthWire)--April 26, 2002--
VARIAGENICS, INC. (Nasdaq: VGNX - news), a leader in pharmacogenomics, today announced that it will take part in a panel discussion entitled "Pharmacogenomics: The Convergence of Diagnostics and Therapeutics" at the Thomas Weisel Partners Healthcare Tailwinds Conference. The discussion is scheduled for Monday, April 29, 2002 at 2:00 p.m. (Eastern Time). This event will be webcast live and may be accessed at www.variagenics.com. The replay will be available for two weeks after the event.
Jay Mohr, VARIAGENICS' President and Chief Business Officer, will participate in the panel discussion. The event will take place at the Four Season's Hotel in Boston, MA.
VARIAGENICS, INC. applies its pharmacogenomic technologies to the discovery, development and commercialization of personalized drugs and companion molecular diagnostic products. Using a drug pathway approach, the Company identifies therapeutically important genetic markers, including SNPs, haplotypes and LOH indicators. This information is then applied to clinical programs to enhance drugs in development, and ultimately to the creation of diagnostics for predicting patient response to drugs. |
